Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01578486 · ClinicalTrials.gov registry record · Phase 4

Salsalate as an Adjunctive Treatment for Patients With Schizophrenia

A Phase 4 study, sponsored by University of Massachusetts, Worcester.

Completed
Registry status
Phase 4
Development phase
17
Enrollment target

NCT01578486 is a Phase 4 study that has completed, run by University of Massachusetts, Worcester. The registered enrollment target is 17 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01578486, a Phase 4 study, has completed, sponsored by University of Massachusetts, Worcester.

COMPLETED
Registry status
Phase 4
Development phase
17 participants
Enrollment target

Study Summary

This is a 12-week, open-label trial of salsalate 3 g/day as an adjunctive treatment in 15 schizophrenia subjects to examine salsalate's effect on psychopathology, cognitive functioning, and metabolic parameters. Potential subjects will be identified by their clinicians at the Freedom Trail Clinic, or Massachusetts General Hospital. A total of 15 subjects will be enrolled.

Interventions

  • DRUG salsalate

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2011-06
Est. Completion 2015-07
Phase Phase 4

What the Registry Record Tells You About NCT01578486

The ClinicalTrials.gov registry entry for NCT01578486 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Massachusetts, Worcester, which has 240 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which salsalate is the first listed.

NCT01578486 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01578486 about?

NCT01578486 is a clinical study titled "Salsalate as an Adjunctive Treatment for Patients With Schizophrenia". This is a 12-week, open-label trial of salsalate 3 g/day as an adjunctive treatment in 15 schizophrenia subjects to examine salsalate's effect on psychopathology, cognitive functioning, and metabolic parameters. Potential subjects will be identified by their clinicians at the Freedom Trail Clinic, ...

What is the current status of trial NCT01578486?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 17 participants. The study started on 2011-06. Estimated completion is 2015-07.

What interventions are being tested in trial NCT01578486?

The interventions under investigation include: salsalate (DRUG).

Who is sponsoring clinical trial NCT01578486?

This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.